Target intelligence / Profile preview

Major fimbrial subunit MrkA (MrkA)

Target
MrkA
Molecular classification
Bacterial fimbrial protein, Pilin, Adhesin subunit
01

Overview

The Major fimbrial subunit MrkA is the primary structural protein of the type 3 fimbriae in Klebsiella pneumoniae, a significant Gram-negative opportunistic pathogen [1, 11]. These fimbriae are helix-shaped appendages that play a critical role in bacterial colonization by mediating adhesion to both biotic host tissues and abiotic surfaces, such as urinary catheters and endotracheal tubes [3, 4, 13]. While the associated MrkD adhesin facilitates specific binding to collagen, the MrkA shaft is the predominant factor driving the formation of dense, mature biofilms, which protect the bacteria from host immune responses and conventional antibiotic treatment [1, 6]. MrkA is highly conserved across various clinical isolates of K. pneumoniae, making it an attractive target for anti-virulence and immunotherapy strategies [7, 12]. Experimental monoclonal antibodies targeting MrkA have demonstrated the ability to inhibit biofilm formation and promote opsonophagocytic killing in preclinical models of pneumonia and sepsis [5, 10]. However, a significant therapeutic challenge is the heterogeneous expression of MrkA, as sub-populations of bacteria that do not express the fimbriae can evade antibody-mediated clearance, potentially limiting the efficacy of these treatments in certain infection stages [10, 12].

Other names
Fimbrial subunit type 3Type 3 fimbrial subunitMajor pilin MrkAMrkA fimbrial proteinPilin subunit MrkA
02

Mechanism of action

Inhibition of bacterial adhesion to host and abiotic surfaces, disruption of biofilm formation, and enhancement of opsonophagocytic killing by host immune cells

03

Biological functions

Cell adhesionBiofilm formationFimbrial assemblyBacterial colonizationAttachment to abiotic surfaces
04

Disease associations

InfectionPneumoniaUrinary tract infectionSepsisCatheter-associated infection
05

Safety considerations

Immune evasion due to heterogeneous expression within bacterial populationsPhase variation of fimbriae expressionPotential for limited therapeutic efficacy if bacteria downregulate the target during systemic infection
06

Interacting drugs

Anti-MrkA monoclonal antibody

1 more in the full profile.

07

Biomarkers

MrkA expression levelmrkABCDF operon presenceType 3 fimbriae production

Beyond the preview

Go deeper on Major fimbrial subunit MrkA (MrkA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major fimbrial subunit MrkA (MrkA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call